Hims & Hers Health (NYSE:HIMS) Given Hold (C+) Rating at Weiss Ratings

Key Points

• Weiss Ratings has reissued a "hold (C+)" rating for Hims & Hers Health, while other analysts have varied ratings, including a "buy" from Canaccord Genuity and a "sell" from Citigroup.
• The stock's performance shows a recent trading price of $53.80 with a market cap of $12.16 billion and significant fluctuations, having reached a 1-year high of $72.98.
• Hims & Hers Health reported a 72.6% increase in revenue year-over-year but missed earnings estimates, posting $0.17 EPS compared to a consensus of $0.18.

Hims & Hers Health (NYSE:HIMS - Get Free Report)'s stock had its "hold (c+)" rating reissued by analysts at Weiss Ratings in a research note issued to investors on Tuesday,Weiss Ratings reports.

Other research analysts have also issued reports about the company. Canaccord Genuity Group reiterated a "buy" rating and set a $68.00 price target on shares of Hims & Hers Health in a report on Friday, September 12th. Wall Street Zen lowered Hims & Hers Health from a "buy" rating to a "hold" rating in a report on Monday, July 28th. Needham & Company LLC reiterated a "hold" rating on shares of Hims & Hers Health in a report on Tuesday, August 5th. Truist Financial cut their price target on Hims & Hers Health from $48.00 to $37.00 and set a "hold" rating for the company in a report on Monday, August 18th. Finally, Citigroup restated a "sell" rating on shares of Hims & Hers Health in a research note on Monday, June 23rd. Two investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus price target of $38.92.

Hims & Hers Health Stock Performance

HIMS traded down $0.93 on Tuesday, hitting $53.80. The company had a trading volume of 7,791,844 shares, compared to its average volume of 32,488,348. The company's fifty day moving average price is $50.69 and its 200 day moving average price is $48.29. Hims & Hers Health has a 1-year low of $18.33 and a 1-year high of $72.98. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The stock has a market cap of $12.16 billion, a price-to-earnings ratio of 67.38, a price-to-earnings-growth ratio of 3.65 and a beta of 2.25.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.01). Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. During the same quarter last year, the firm posted $0.06 earnings per share. The firm's revenue for the quarter was up 72.6% compared to the same quarter last year. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities analysts predict that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,021 shares of the company's stock in a transaction on Wednesday, September 17th. The stock was sold at an average price of $50.50, for a total value of $506,060.50. Following the sale, the insider directly owned 169,940 shares in the company, valued at $8,581,970. This represents a 5.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Michael Chi sold 2,100 shares of the company's stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $56.52, for a total value of $118,692.00. Following the completion of the sale, the insider owned 291,439 shares in the company, valued at $16,472,132.28. This trade represents a 0.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,608,588 shares of company stock valued at $83,020,063. 17.71% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

A number of large investors have recently bought and sold shares of the stock. Signaturefd LLC grew its holdings in shares of Hims & Hers Health by 17.7% during the first quarter. Signaturefd LLC now owns 2,586 shares of the company's stock worth $76,000 after purchasing an additional 388 shares during the last quarter. Lake Hills Wealth Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter worth $277,000. Occidental Asset Management LLC bought a new stake in shares of Hims & Hers Health during the second quarter worth $305,000. Dakota Wealth Management bought a new stake in shares of Hims & Hers Health during the second quarter worth $354,000. Finally, Fiduciary Alliance LLC grew its holdings in shares of Hims & Hers Health by 120.4% during the second quarter. Fiduciary Alliance LLC now owns 109,253 shares of the company's stock worth $5,446,000 after purchasing an additional 59,686 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.